…
Humanoid, Inc., through its subsidiaries, designs, develops, manufactures, and markets farming and sideline products; chemical materials and products; textiles; construction materials; and livestock and poultry products. It cultivates, processes, markets, and distributes various food and agro-byproducts; and manufactures and supplies nutrition and healthcare products. The company's products portfolio includes cotton and wool, sorghum, grains, barley, soybean, alfalfa, corn, and wheat; onions, beets, lupin, bell peppers, potato, peas, carrots, and brussels potato; fuji apple, wolf berry, water melons, apricots, hami melons, peaches, chinese pear, tomato, grapes, dates, yellow river melons, and medlar; hops, nursery crops, liquorices root, flaxseed, aloe plant, TCM herbs, and ginseng; oil seeds, black melon, sunflower, corn; and chicken, pigs, sheep, eggs, and cows. In addition, it produces drip irrigation equipment, fertilizers, and animal feeds; and engages in the acquisition and development of gold, silver, and other mineral properties. The company operates in the United States, the People's Republic of China, and the Philippines. Humanoid, Inc. also exports its products. The company was formerly known as YaSheng Group and changed its name to Humanoid, Inc. in April 2024. The company was founded in 1998 and is headquartered in Sunnyvale, California. Humanoid, Inc. is a subsidiary of Gansu Yasheng Salt Chemical Industrial Group, Ltd.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public disclosures for Yasheng Group (HERB.US), an OTC Pink–listed company, are limited and provide few verifiable details about its operations. Available descriptions reference consumer health products; long-term growth for such businesses may be supported by aging demographics and rising wellness spending, so investors may find upside if management can substantiate consistent revenue and regulatory compliance.
Key risks are limited disclosure and transparency, low liquidity, weak governance and execution risk common to OTC Pink microcaps, which investors should monitor.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | 8.07M | 7.02M | 5.31M | 3.72M | 2.99M |
| Net income | 8.07M | 7.02M | 5.31M | 3.72M | 2.99M |
| Selling general administrative | 0.10M | 0.08M | 0.07M | 0.06M | 0.04M |
| Selling and marketing expenses | 0.78M | 0.70M | 0.61M | 0.50M | 0.46M |
| Gross profit | 8.08M | 7.04M | 5.59M | 4.01M | 3.24M |
| Ebit | 7.20M | 7.02M | 4.91M | 3.46M | 2.74M |
| Ebitda | 7.66M | 7.42M | 5.21M | 3.76M | 3.02M |
| Depreciation and amortization | 0.46M | 0.40M | 0.30M | 0.30M | 0.28M |
| Operating income | 7.20M | 6.26M | 4.91M | 3.46M | 2.74M |
| Other operating expenses | 16.95M | 14.88M | 13.68M | 10.56M | 9.81M |
| Interest expense | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Income tax expense | - | 7.02M | 0.00M | -0.00M | -0.00M |
| Total revenue | 24.15M | 21.14M | 18.59M | 14.01M | 12.55M |
| Total operating expenses | 0.88M | 0.78M | 0.68M | 0.56M | 0.50M |
| Cost of revenue | 16.07M | 14.10M | 13.00M | 10.00M | 9.31M |
| Total other income expense net | 0.87M | 0.76M | 0.40M | 0.26M | 0.25M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 290.25M | 274.75M | 268.65M | 265.10M | 264.71M |
| Intangible assets | 125.12M | 124.22M | 123.00M | 122.81M | 122.74M |
| Other current assets | 0.83M | 0.69M | 0.45M | 0.13M | 0.21M |
| Total liab | 6.16M | 5.77M | 4.57M | 3.42M | 3.97M |
| Total stockholder equity | 284.08M | 268.98M | 264.08M | 261.68M | 260.74M |
| Other current liab | 3.35M | 3.12M | 2.31M | 0.82M | 0.62M |
| Common stock | 157.17M | 157.17M | 157.17M | 157.17M | 157.17M |
| Retained earnings | 8.07M | 7.02M | 5.31M | 3.72M | 2.99M |
| Other assets | - | - | 0.00M | 0.00M | 0.00M |
| Cash | 8.53M | 6.08M | 4.18M | 3.75M | 3.35M |
| Total current liabilities | 4.26M | 3.92M | 3.07M | 2.35M | 2.70M |
| Net debt | -8.30M | -4.03M | -2.49M | -1.52M | -0.57M |
| Short term debt | 0.23M | 0.20M | 0.19M | 1.17M | 1.52M |
| Short long term debt total | 0.23M | 2.05M | 1.69M | 2.23M | 2.78M |
| Other stockholder equity | - | -5.77M | -4.57M | -3.42M | -3.97M |
| Total current assets | 13.79M | 10.61M | 7.65M | 7.86M | 8.85M |
| Net receivables | 1.51M | 1.28M | 0.97M | 1.00M | 0.90M |
| Inventory | 2.93M | 2.57M | 2.06M | 2.98M | 4.40M |
| Accounts payable | 0.68M | 0.60M | 0.58M | 0.37M | 0.57M |
| Accumulated other comprehensive income | 118.85M | 110.57M | 106.18M | 104.22M | 104.55M |
| Non currrent assets other | - | 124.22M | 0.00M | 0.00M | 0.00M |
| Non current assets total | 276.46M | 264.14M | 261.00M | 257.24M | 255.86M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total cashflows from investing activities | -3.13M | -2.02M | -2.32M | -0.50M | -0.34M |
| Total cash from financing activities | -0.55M | -0.43M | 0.66M | 0.25M | 0.21M |
| Net income | 8.07M | 7.02M | 5.31M | 3.72M | 2.99M |
| Change in cash | 2.45M | 1.90M | 0.42M | 0.40M | 1.21M |
| Begin period cash flow | 6.08M | 4.18M | 3.75M | 3.35M | 2.14M |
| End period cash flow | 8.53M | 6.08M | 4.18M | 3.75M | 3.35M |
| Total cash from operating activities | 5.49M | 3.77M | 2.40M | 2.44M | -0.55M |
| Depreciation | 0.46M | 0.40M | 0.30M | 0.30M | 0.28M |
| Other cashflows from investing activities | -0.38M | 0.00M | 0.00M | -1.79M | - |
| Change to inventory | -3.40M | -3.57M | -3.06M | -2.98M | -4.40M |
| Change to account receivables | -1.45M | -1.28M | -0.97M | -0.74M | -0.90M |
| Other cashflows from financing activities | -0.55M | -0.43M | 0.66M | -0.25M | 0.21M |
| Capital expenditures | 2.75M | 1.05M | 2.00M | 0.50M | 0.34M |
| Change in working capital | -4.41M | -5.74M | -5.00M | -4.57M | -6.42M |
| Other non cash items | 1.37M | 2.10M | 1.79M | 2.99M | 2.59M |
| Free cash flow | 2.74M | 2.72M | 0.40M | 1.94M | -0.89M |
Sector: Consumer Defensive Industry: Farm Products
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| HERB Yasheng Group |
- -% |
0.01 | 0.03 | - | 0.21 | - | 0.08 | 0.62 |
| ADM Archer-Daniels-Midland Company |
0.36 0.52% |
70.20 | 23.66 | 16.45 | 0.51 | 1.77 | 0.61 | 12.88 |
| BG Bunge Global SA |
-0.71 0.70% |
100.47 | 25.52 | 14.53 | 0.35 | 1.53 | 0.54 | 15.43 |
| TSN Tyson Foods Inc |
1.18 1.96% |
61.05 | - | 24.94 | 0.34 | 1.00 | 0.51 | 26.68 |
| MNHVF Mowi ASA |
- -% |
23.55 | 15.54 | 15.90 | 1.89 | 2.37 | 2.20 | 9.26 |
Humanoid, Inc., through its subsidiaries, designs, develops, manufactures, and markets farming and sideline products; chemical materials and products; textiles; construction materials; and livestock and poultry products. It cultivates, processes, markets, and distributes various food and agro-byproducts; and manufactures and supplies nutrition and healthcare products. The company's products portfolio includes cotton and wool, sorghum, grains, barley, soybean, alfalfa, corn, and wheat; onions, beets, lupin, bell peppers, potato, peas, carrots, and brussels potato; fuji apple, wolf berry, water melons, apricots, hami melons, peaches, chinese pear, tomato, grapes, dates, yellow river melons, and medlar; hops, nursery crops, liquorices root, flaxseed, aloe plant, TCM herbs, and ginseng; oil seeds, black melon, sunflower, corn; and chicken, pigs, sheep, eggs, and cows. In addition, it produces drip irrigation equipment, fertilizers, and animal feeds; and engages in the acquisition and development of gold, silver, and other mineral properties. The company operates in the United States, the People's Republic of China, and the Philippines. Humanoid, Inc. also exports its products. The company was formerly known as YaSheng Group and changed its name to Humanoid, Inc. in April 2024. The company was founded in 1998 and is headquartered in Sunnyvale, California. Humanoid, Inc. is a subsidiary of Gansu Yasheng Salt Chemical Industrial Group, Ltd.
710 Lakeway Drive, Sunnyvale, CA, United States, 94085
86 93 1885 7181
10000
| Name | Title | Year Born |
|---|---|---|
| Mr. Haiyun Zhuang | CFO, Treasurer, Sec. & Director | 1970 |
| Mr. Weihao Cui | CEO, Pres & Director | 1972 |
| Mr. Darong Liu | COO & Director | 1966 |
| Mr. Robert Cardinal | Sr. Financial Officer & Director | 1952 |
| Mr. Chen Eric Christopher | Sr. VP & Director | 1959 |
| Mr. Jia Mao Li | Pres of Gansu Xiaheqing Industrial Co | 1958 |
| Mr. Sheng Jing Luo | Pres of Gansu Tiaoshan Agro-Ind-Com Group Co and Pres of Gansu YaSheng Salt Ind | 1948 |
| Mr. Haiyun Zhuang | CFO, Treasurer, Secretary & Director | 1970 |
| Mr. Weihao Cui | CEO, President & Director | 1972 |
| Mr. Robert Cardinal | Senior Financial Officer & Director | 1952 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.